Cargando…

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure

Recognition that neurohormonal activation plays a central role in the pathogenesis of heart failure (HF) led to the development of angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers, mineralocorticoid receptor antagonists and beta blockers. While there has been substanti...

Descripción completa

Detalles Bibliográficos
Autor principal:	Greenberg, Barry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Heart Failure 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536660/ https://www.ncbi.nlm.nih.gov/pubmed/36263291 http://dx.doi.org/10.36628/ijhf.2020.0002

Ejemplares similares

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists
por: Dalal, Jamshed, et al.
Publicado: (2023)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study
por: Wang, Xiaobo, et al.
Publicado: (2023)

Effects of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) on the Glucose and Fat Metabolism Biomarkers Leptin and Fructosamine
por: Ohnewein, Bernhard, et al.
Publicado: (2023)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
por: Rattanavipanon, Wipharak, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J. V., et al.
Publicado: (2013)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
por: Cho, In-Jeong, et al.
Publicado: (2021)

Beneficial Effects of Combined AT(1) Receptor/Neprilysin Inhibition (ARNI) Versus AT(1) Receptor Blockade Alone in the Diabetic Eye
por: Prasad, Tuhina, et al.
Publicado: (2016)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
por: Choi, Hong-Mi, et al.
Publicado: (2020)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
por: Kashiwagi, Yusuke, et al.
Publicado: (2023)

Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper
por: Ntalianis, Argyrios, et al.
Publicado: (2021)

Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism
por: Kashiwagi, Yusuke, et al.
Publicado: (2022)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
por: Sun, Yuxi, et al.
Publicado: (2021)

Chronic kidney disease, heart failure and neprilysin inhibition
por: Haynes, Richard, et al.
Publicado: (2020)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Is there a place for angiotensin receptor-neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?
por: Gulin, Dario, et al.
Publicado: (2019)

The Impact of Angiotensin Receptor–Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis
por: Mujadzic, Hata, et al.
Publicado: (2022)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure
por: Ding, Kun, et al.
Publicado: (2022)

Impact of angiotensin receptor–neprilysin inhibition on vascular function in heart failure with reduced ejection fraction: A pilot study
por: Nathaniel, Sangeetha, et al.
Publicado: (2022)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
por: Taghavi, Sepideh, et al.
Publicado: (2020)

Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure
por: Pfau, Daniel, et al.
Publicado: (2019)

Monitoring the Effectiveness and Safety of ARNI vs. Angiotensin Receptor Blocker by Frailty Status
por: Kim, Dae, et al.
Publicado: (2021)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure
por: Mukhopadhyay, Amrita, et al.
Publicado: (2022)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction
por: Grant, Andrew D.M., et al.
Publicado: (2020)

Increased concentrations of bioactive adrenomedullin subsequently to angiotensin‐receptor/neprilysin‐inhibitor treatment in chronic systolic heart failure
por: Arfsten, Henrike, et al.
Publicado: (2020)

Long‐term impact of angiotensin receptor‐neprilysin inhibitor based on short‐term treatment response in heart failure
por: Park, Hyuk Kyoon, et al.
Publicado: (2023)

Real-world Practical Experience of Angiotensin Receptor-neprilysin Inhibitor in Older Japanese Patients with Chronic Heart Failure
por: Komatsu, Toshinori, et al.
Publicado: (2023)

Trends of ARNI and Other Heart Failure Medication Use in Older Adults
por: Lee, Yu-Chien, et al.
Publicado: (2021)

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
por: Nishikimi, Toshio, et al.
Publicado: (2022)

Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials
por: Bratsos, Sosipatros
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pf3mqna279bmv6qlpups258b3p